
André Oliveira Baldoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/659798/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Frequency of A1C tests undertaken by patients assisted by pharmaceutical care services in Brazil. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102380.	3.6	0
2	Deprescribing clonazepam in primary care older patients: a feasibility study. International Journal of Clinical Pharmacy, 2022, 44, 489-498.	2.1	3
3	Potenciais interações medicamentosas graves em pacientes com doença renal crônica não dialÃŧica: uma frequência preocupante. Research, Society and Development, 2022, 11, e36311124907.	0.1	0
4	Data sources for drug utilization research in Latin American countries—A crossâ€national study: <scp>DASDURâ€LATAM</scp> study. Pharmacoepidemiology and Drug Safety, 2022, 31, 343-352.	1.9	6
5	Is screening for chronic kidney disease in patients with diabetes mellitus being properly conducted in primary care?. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022, , .	0.9	0
6	Population Pharmacokinetic Model of Piperacillin in Critically III Patients and Describing Interethnic Variation Using External Validation. Antibiotics, 2022, 11, 434.	3.7	1
7	Dispensação de medicamentos: conhecimento dos pacientes/cuidadores e perfil dos responsáveis pelo serviço. Research, Society and Development, 2022, 11, e53411326782.	0.1	0
8	Implementation of a text messaging intervention to patients on warfarin therapy in Brazilian primary care units: a quasi-experimental study. , 2022, 23, 54.		1
9	Quality of clinical studies present in the package inserts of coagulation factors used in the treatment of hemophilia. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6859.	0.7	0
10	Avaliação econômica de uma estratégia individual de empoderamento farmacoterapêutico: um modelo em longo prazo aplicado do diabetes mellitus tipo II. Journal of Health & Biological Sciences, 2022, 10, 1.	0.2	0
11	Clinical and humanistic impact of pharmacotherapeutic follow-up in patients with type 1 diabetes mellitus treated judicially. Diabetology and Metabolic Syndrome, 2022, 14, 61.	2.7	1
12	O uso de fármacos anticolinérgicos e fatores associados em adultos de meia-idade e idosos. Ciencia E Saude Coletiva, 2022, 27, 2279-2290.	0.5	2
13	Notas técnicas para judicialização de anticoagulantes orais diretos: uma avaliação do perfil. Medicina, 2022, 55, .	0.1	0
14	Influência da polifarmácia e do uso de medicamentos inapropriados para idosos sobre a taxa de filtração glomerular. Research, Society and Development, 2021, 10, e31810414239.	0.1	0
15	Potenciais interações medicamentosas graves no ambiente hospitalar: Validação de mensagens de alerta para uso em software de prescrição eletrônica. Revista Brasileira De Farmácia Hospitalar E Serviços De Saúde, 2021, 12, 568.	0.1	0
16	Sinais macroscópicos de deterioração de medicamentos em estoques caseiros. Research, Society and Development, 2021, 10, e28910716517.	0.1	0
17	Medicamentos psicotrópicos para idosos: Quais especialidades médicas mais prescrevem?. Research, Society and Development, 2021, 10, e32910918075.	0.1	0
18	Desenvolvimento e validação de um CHECKLIST de atividades geradoras de custo da instância municipal da cadeia de frio de conservação de imunobiológicos. Research, Society and Development, 2021, 10, e22510918044.	0.1	0

#	Article	IF	CITATIONS
19	Evaluation of the potential environmental risk from the destination of medicines: an epidemiological and toxicological study. DARU, Journal of Pharmaceutical Sciences, 2021, 29, 61-71.	2.0	5
20	Alendronato de sódio, levotiroxina e inibidores da bomba de prótons. Revista Brasileira De Medicina De FamÃlia E Comunidade, 2021, 16, 2486.	0.4	0
21	Hospital pharmacy practice and medication errors in Brazil. European Journal of Hospital Pharmacy, 2021, 28, 168-169.	1.1	1
22	Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?. Journal of Evaluation in Clinical Practice, 2020, 26, 957-961.	1.8	1
23	Omeprazole use and risk of chronic kidney disease evolution. PLoS ONE, 2020, 15, e0229344.	2.5	19
24	Obesity and ABO blood group: Is there an association?. Obesity Medicine, 2020, 18, 100209.	0.9	5
25	Use of more expensive insulin despite guidelines in Brazil. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 155-157.	3.6	0
26	Storage and disposal of expired medicines in home pharmacies: emerging public health problems. Einstein (Sao Paulo, Brazil), 2020, 18, eAO5066.	0.7	10
27	Elaboração e validação do protocolo de desprescrição do clonazepam em idosos. Revista Brasileira De Medicina De FamÃłia E Comunidade, 2020, 15, 2105.	0.4	4
28	Potential drug interactions and inappropriate medications prescribed for primary health care users. Revista Brasileira De Farmácia Hospitalar E Serviços De Saúde, 2020, 11, 0365.	0.1	0
29	Software for dose adjustment of antimicrobials. Implications for plasma concentrations and pratical limitations. Einstein (Sao Paulo, Brazil), 2020, 18, eCE5858.	0.7	0
30	Cardiovascular drug labeling: Do they have information on necessary precautions for older people?. Geriatrics Gerontology and Aging, 2020, 14, 196-202.	0.3	2
31	Prevalência e fatores associados à presença de medicamentos vencidos em estoques caseiros. Cadernos Saude Coletiva, 2020, 28, 390-399.	0.6	2
32	Irrational use of alendronate sodium by the elderly. Revista Brasileira De Medicina De FamÃ l ia E Comunidade, 2020, 15, 2310.	0.4	0
33	Pacientes com diabetes mellitus tipo 2 em uso de medicamentos via judicial. Revista Brasileira De Medicina De FamÃlia E Comunidade, 2020, 15, 2561.	0.4	0
34	Epidemiological profile of isolated bacteria in a public pediatric hospital. Revista De Epidemiologia E Controle De Infecção, 2020, 10, .	0.0	0
35	Omeprazole use and risk of chronic kidney disease evolution. , 2020, 15, e0229344.		0

Omeprazole use and risk of chronic kidney disease evolution. , 2020, 15, e0229344.

0

#	Article	IF	CITATIONS
37	Omeprazole use and risk of chronic kidney disease evolution. , 2020, 15, e0229344.		0
38	Omeprazole use and risk of chronic kidney disease evolution. , 2020, 15, e0229344.		0
39	Pharmacotherapeutic empowerment and its effectiveness in glycemic control in patients with Diabetes Mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 137-142.	3.6	12
40	Patients with chronic kidney disease and diabetes mellitus: How is health care?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2292-2298.	3.6	1
41	Post-marketing Study of Linagliptin: A Pilot Study. Frontiers in Pharmacology, 2019, 10, 576.	3.5	2
42	What is the effectiveness of post-discharge pharmacotherapeutic empowerment of patients with diabetes?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1321-1323.	3.6	0
43	Patients participation in pharmaceutical care consultations in Brazil. International Journal of Clinical Pharmacy, 2019, 41, 677-681.	2.1	3
44	Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2019, 7, e000647.	2.8	2
45	A Distance-Learning Course to Improve Drug-Dispensing Behaviors Among Brazilian Community Pharmacists. American Journal of Pharmaceutical Education, 2019, 83, 6874.	2.1	2
46	EDUCAÇÃO E MEDIDAS NÃO FARMACOLÓGICAS QUE PROMOVAM UMA BOA QUALIDADE DO SONO: UMA NECESSIDADE EMERGENTE PARA OS IDOSOS. Revista Brasileira De Extensão Universitária, 2019, 10, 35-42.	0.0	2
47	What is the association between social capital and diabetes mellitus? A systematic review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 601-605.	3.6	16
48	Drugâ€resistant epilepsy and topiramate: Plasma concentration and frequency of epileptic seizures. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 652-658.	1.9	0
49	Patients lacking glycemic control place more burdens on health services with the use of medications. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 279-283.	3.6	6
50	Effectiveness of individual strategies for the empowerment of patients with diabetes mellitus: A systematic review with meta-analysis. Primary Care Diabetes, 2018, 12, 97-110.	1.8	31
51	Pharmacists in dispensing drugs (PharmDisp): protocol for a clinical trial to test the effectiveness of distance education in training pharmacists for dispensing drugs. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	0
52	Economic Evaluations in Health from the Perspective of the Costs Associated with Diabetes Mellitus Treatment. , 2018, , .		0
53	Linagliptin safety profile: A systematic review. Primary Care Diabetes, 2018, 12, 477-490.	1.8	6
54	Hospital pharmacy workforce in Brazil. Human Resources for Health, 2018, 16, 1.	3.1	64

#	Article	IF	CITATIONS
55	Influence of the clinical profile of patients with refractory epilepsy on lamotrigine plasma concentration. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	0
56	Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis. European Journal of Clinical Pharmacology, 2017, 73, 1341-1353.	1.9	14
57	Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S859-S865.	3.6	8
58	Collective empowerment strategies for patients with Diabetes Mellitus: A systematic review and meta-analysis. Primary Care Diabetes, 2017, 11, 201-211.	1.8	32
59	Cartilha educativa sobre diabetes: elaboração e validação de conteúdo. Semina: Ciências Biológicas E Da Saúde, 2016, 37, 77.	0.2	1
60	Evaluation of the effectiveness of an Internet-based continuing education program on pharmacy-based minor ailment management: a randomized controlled clinical trial. Brazilian Journal of Pharmaceutical Sciences, 2016, 52, 15-26.	1.2	1
61	An investigation of the influence of patientâ€related factors and comedications on lamotrigine clearance in patients with epilepsy. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 685-689.	1.9	3
62	A Systematic Review of the Effects of Continuing Education Programs on Providing Clinical Community Pharmacy Services. American Journal of Pharmaceutical Education, 2016, 80, 88.	2.1	23
63	Economic Evaluation of a Pharmaceutical Care Program for Elderly Diabetic and Hypertensive Patients in Primary Health Care: A 36-Month Randomized Controlled Clinical Trial. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 66-75.	0.9	54
64	Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. International Journal of Clinical Pharmacy, 2014, 36, 45-54.	2.1	56
65	Factors associated with potentially inappropriate medications use by the elderly according to Beers criteria 2003 and 2012. International Journal of Clinical Pharmacy, 2014, 36, 316-324.	2.1	58
66	Drug utilization profile in adult patients with refractory epilepsy at a tertiary referral center. Arquivos De Neuro-Psiquiatria, 2013, 71, 856-861.	0.8	7
67	Pharmacoepidemiological profile and polypharmacy indicators in elderly outpatients. Brazilian Journal of Pharmaceutical Sciences, 2013, 49, 443-452.	1.2	12
68	Use of Simulated Patients to Evaluate Combined Oral Contraceptive Dispensing Practices of Community Pharmacists. PLoS ONE, 2013, 8, e79875.	2.5	24
69	Adverse drug reactions caused by drug–drug interactions in elderly outpatients: a prospective cohort study. European Journal of Clinical Pharmacology, 2012, 68, 1667-1676.	1.9	77
70	Prevalence and Predictors of Potential Drug-Drug Interactions in the Elderly: A Cross-Sectional Study in the Brazilian Primary Public Health System. Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 344.	2.1	41
71	Incidence and Predictors of Adverse Drug Reactions Caused by Drug-Drug Interactions in Elderly Outpatients: A Prospective Cohort Study. Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 332.	2.1	43
72	Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. International Journal of Clinical Pharmacy, 2011, 33, 642-649.	2.1	78

#	Article	IF	CITATIONS
73	FONTES DE INFORMAÇÕES SOBRE INTERAÇÕES MEDICAMENTOSAS: HÕCONCORDÃ,NCIA ENTRE ELAS?. Revista Da Universidade Vale Do Rio Verde, 2011, 9, 84-91.	0.1	6
74	A FARMACOEPIDEMIOLOGIA NO BRASIL: ESTADO DA ARTE DA PRODUÇÃ∫O CIENTÃFICA. Revista Da Universidade Vale Do Rio Verde, 2011, 9, 78-88.	0.1	5
75	Elderly and drugs: risks and necessity of rational use. Brazilian Journal of Pharmaceutical Sciences, 2010, 46, 617-632.	1.2	17
76	Potentially inappropriate medication use in older adults: prevalence and physician knowledge. Geriatrics Gerontology and Aging, 0, 15, .	0.3	2
77	Deprescribing benzodiazepines: Do Brazilian package inserts address this issue?. Geriatrics Gerontology and Aging, 0, 15, .	0.3	0
78	Barriers and enablers to deprescribing benzodiazepines in older adults: elaborating an instrument and validating its content. Geriatrics Gerontology and Aging, 0, 15, .	0.3	0
79	Sodium alendronate: proposal and reliability of indicators. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
80	Medications used in paediatric intensive care by continuous infusion: Do the technical aspects of the package inserts corroborate scientific evidence?. Journal of Clinical Pharmacy and Therapeutics, 0, , .	1.5	0
81	Factors associated with falls in frail older persons—a case control study in Brazil. Ageing International, 0, , .	1.3	0